Shechter Michael, Hod Hanoch, Rabinowitz Babeth, Boyko Valentina, Chouraqui Pierre
Heart Institute, Sheba Medical Center, Tel-Hashomer and Sackler School of Medicine, Tel-Aviv University, Tel Hashomer, Israel.
Cardiology. 2003;99(4):205-10. doi: 10.1159/000071250.
The aim of our study was to analyze the long-term survival and cardiac function in 194 consecutive, thrombolysis-ineligible acute myocardial infarction (AMI) patients receiving 48-hour intravenous magnesium sulfate (22 g) - 96 patients, compared with placebo - 98 patients. After a mean 4.8-year follow-up, all-cause mortality and cardiac mortality were significantly lower in the magnesium compared to the placebo group [(18 vs. 33 patients, p < 0.01) and (12 vs. 30 patients, p < 0.001), respectively]. Rest radionuclide ventriculography tests for left-ventricular ejection fraction (LVEF) were assessed in surviving patients up to completion of follow-up. Magnesium-treated patients had a significantly higher LVEF (0.51 +/- 0.10 vs. 0.44 +/- 0.14, p < 0.05) and a lower incidence of heart failure compared to placebo-treated patients (12 vs. 3 patients, p = 0.02). Beneficial effects of intravenous magnesium therapy in thrombolysis-ineligible AMI patients appeared to last for at least 4.8 years, concomitant with preserved LVEF, suggesting a favorable role for acute magnesium treatment in these patients.
我们研究的目的是分析194例连续的、不符合溶栓治疗条件的急性心肌梗死（AMI）患者的长期生存率和心功能。这些患者接受了48小时静脉注射硫酸镁（22克）——96例患者，与接受安慰剂治疗的98例患者进行比较。经过平均4.8年的随访，硫酸镁治疗组的全因死亡率和心脏死亡率显著低于安慰剂组[分别为（18例对33例患者，p<0.01）和（12例对30例患者，p<0.001）]。对存活患者进行静息放射性核素心室造影检查以评估左心室射血分数（LVEF），直至随访结束。与接受安慰剂治疗的患者相比，接受硫酸镁治疗的患者LVEF显著更高（0.51±0.10对0.44±0.14，p<0.05），心力衰竭发生率更低（12例对3例患者，p = 0.02）。静脉注射硫酸镁治疗对不符合溶栓治疗条件的AMI患者的有益作用似乎持续至少4.8年，同时LVEF得以保留，提示急性镁治疗在这些患者中具有有利作用。
